AKRO Akero Therapeutics Inc

Price (delayed)

$37.45

Market cap

$1.76B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.87

Enterprise value

$1.52B

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, ...

Highlights

Akero Therapeutics's quick ratio has surged by 146% YoY and by 24% QoQ

Akero Therapeutics's EPS has increased by 15% QoQ

AKRO's equity has surged by 93% year-on-year but it is down by 4.9% since the previous quarter

AKRO's net income is down by 11% YoY but it is up by 8% QoQ

Sector: Healthcare

Industry: Biotechnology

Website: http://www.akerotx.com

Peers: OVID

Key stats

What are the main financial stats of AKRO

Market

Shares outstanding

46.97M

Market cap

$1.76B

Enterprise value

$1.52B

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

5.36

Price to sales (P/S)

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Earnings

Revenue

EBIT

-$111.29M

EBITDA

-$111.03M

Free cash flow

-$92.52M

Per share

EPS

-$2.87

Free cash flow per share

-$2.37

Book value per share

$6.98

Revenue per share

TBVPS

$9.15

Balance sheet

Total assets

$356.57M

Total liabilities

$30.01M

Debt

$10.62M

Equity

$326.56M

Working capital

$336.09M

Liquidity

Debt to equity

0.03

Current ratio

18.61

Quick ratio

18.42

Net debt/EBITDA

2.15

Margins

EBITDA margin

N/A

Gross margin

N/A

Net margin

N/A

Operating margin

N/A

Efficiency

Return on assets

-41.1%

Return on equity

-46.4%

Return on invested capital

-560.3%

Return on capital employed

-33%

Return on sales

N/A

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

AKRO stock price

How has the Akero Therapeutics stock price performed over time

Intraday

-6%

1 week

-6.91%

1 month

-10.47%

1 year

140.06%

YTD

-31.66%

QTD

-31.66%

Financial performance

How have Akero Therapeutics's revenue and profit performed over time

Revenue

Gross profit

Operating income

-$115.16M

Net income

-$112.03M

Gross margin

N/A

Net margin

N/A

Akero Therapeutics's operating income has decreased by 14% YoY but it has increased by 6% from the previous quarter

AKRO's net income is down by 11% YoY but it is up by 8% QoQ

Growth

What is Akero Therapeutics's growth rate over time

Valuation

What is Akero Therapeutics stock price valuation

P/E

N/A

P/B

5.36

P/S

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Akero Therapeutics's EPS has increased by 15% QoQ

AKRO's equity has surged by 93% year-on-year but it is down by 4.9% since the previous quarter

The stock's P/B is 25% above its last 4 quarters average of 4.3

Efficiency

How efficient is Akero Therapeutics business performance

Akero Therapeutics's return on invested capital has shrunk by 156% YoY but it has surged by 97% QoQ

Akero Therapeutics's return on equity has increased by 23% QoQ and by 3.9% YoY

The ROA has grown by 21% from the previous quarter and by 7% YoY

Dividends

What is AKRO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for AKRO.

Financial health

How did Akero Therapeutics financials performed over time

Akero Therapeutics's quick ratio has surged by 146% YoY and by 24% QoQ

The current ratio has soared by 142% year-on-year and by 24% since the previous quarter

AKRO's debt is 97% smaller than its equity

The debt to equity has soared by 200% YoY

AKRO's equity has surged by 93% year-on-year but it is down by 4.9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.